KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.

Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Vanderson Rocha, Cristina Papayannidis, Jessica T Leonard, Maria R Baer, Jose-Maria Ribera, Yanyu Wu, Meliessa Hennessy, Alexandar Vorog, Shien Guo

Ann Hematol 104(9) 4669-4678

PMID41071292
PMCIDPMC12552232
DOI10.1007/s00277-025-06635-0
发表日期2025-10-10
入排依据:The record describes a health-related quality-of-life (HRQoL) analysis from a Phase III randomized trial. While it is oncology, human, randomized, Phase III, has a drug intervention, and is an original result, its primary analysis and endpoint are not time-to-event efficacy. The abstract focuses on HRQoL outcomes and clinical response as predictors, not on a primary or key secondary time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or survival analyses with Kaplan-Meier or hazard ratios. Therefore, it is excluded per the criteria requiring a time-to-event efficacy endpoint.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

In the phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy, patient-reported treatment tolerability, and health-related quality of life (HRQoL) compared to imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). To explore the association between clinical response and HRQoL and substantiate the superior effect of ponatinib over imatinib on HRQoL, we analyzed the impact of clinical response and treatment tolerability on changes in HRQoL.HRQoL was assessed using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire and the EQ-5D-5 L. Treatment tolerability was assessed using the FACT-GP5 item "bothered by treatment side effects." Linear mixed-effects regression models were used to examine changes in HRQoL over time, with clinical response status and patient-reported overall treatment tolerability as time-varying predictors, while controlling for significant covariates.This analysis included data from 238 patients (159 ponatinib, 79 imatinib). Achieving clinical response (complete remission or incomplete remission) was associated with significantly better changes from baseline across all FACT-Leu domains and the EQ-visual analogue scale than not achieving clinical response (p < 0.05). Treatment-related side effects led to significantly and meaningfully worse changes in HRQoL than "not bothered by treatment," with higher levels of "bother" associated with greater worsening in HRQoL from baseline.Taken together with the better treatment tolerability and longer response duration of ponatinib compared to imatinib, these findings further substantiate the HRQoL benefit of ponatinib over imatinib in patients with Ph + ALL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。